Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
Ledermann, Jonathan A Hackshaw, Allan Kaye, Stan B Jayson, Gordon C Gabra, Hani McNeish, Iain Earl, Helena Perren, Timothy J Gore, Martin Persic, Mojca
Ledermann, Jonathan A
Hackshaw, Allan
Kaye, Stan B
Jayson, Gordon C
Gabra, Hani
McNeish, Iain
Earl, Helena
Perren, Timothy J
Gore, Martin
Persic, Mojca
Citations
Altmetric:
Abstract
Inhibiting angiogenesis is one of the most promising avenues for new therapies for ovarian cancer. We investigated the efficacy and safety of a novel agent, BIBF 1120, a triple angiokinase inhibitor, after chemotherapy for relapsed disease.
Description
Date
2011-10-01
Publisher
Collections
Keywords
Type
Article
Citation
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. 2011, 29 (28):3798-804 J Clin Oncol